Seven-Year PSA ≤ 0.2 ng/mL After High-Dose-Rate Brachytherapy Indicates Eligibility for Discontinuing PSA Surveillance in Prostate Cancer.

ABSTRACT:

Background

We evaluated the long-term treatment outcomes of patients with clinically localized and locally advanced prostate cancer (PC) who underwent high-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy (EBRT). The primary objective was to identify the optimal timing for discontinuing prostate-specific antigen (PSA) monitoring after HDR-BT.

Methods

This analysis included 338 patients with PC who received HDR-BT combined with EBRT between 2006 and 2022 and had a minimum follow-up of 5 years. The patients were stratified based on their PSA levels, and factors associated with recurrence were identified.

Results

The median observation period was 8.9 years (range, 5.0-19.0 years). The 10-year recurrence-free survival rate was 92.0%, with 26 recur

SUBMITTER: Makino T 

PROVIDER: S-EPMC12523830 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature